Dyne Therapeutics, Inc. (DYN) — Financial statements
Income statement, balance sheet, and cash flow for Dyne Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 2↓8.6% | 2↓8.9% | 2 | 0.00 | 0.00 | |
| Gross Profit | -2↑8.6% | -2↑8.9% | -2 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 398↑41.6% | 281↑33.5% | 211↑47.6% | 143↑17.7% | 121 | |
| General & Administrative Expenses | 70↑11.8% | 62↑99.0% | 31↑11.3% | 28↓1.8% | 29 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 70↑11.8% | 62↑99.0% | 31↑11.3% | 28↓1.8% | 29 | |
| Other Expenses | 0.00↑100.0% | -2↑8.9% | -2 | 0.00 | 0.00 | |
| Operating Expenses | 466↑36.4% | 342↑42.5% | 240↑40.2% | 171↑14.0% | 150 | |
| Total Costs & Expenses | 468↑36.1% | 344↑42.0% | 242↑41.6% | 171↑14.0% | 150 | |
| Operating Results | ||||||
| Operating Income | -468↓36.1% | -344↓42.0% | -242↓41.6% | -171↓14.0% | -150 | |
| Depreciation & Amortization | 2↓8.6% | 2↓8.9% | 2↑46.2% | 2↑54.7% | 1 | |
| EBITDA | -438↓39.0% | -315↓35.0% | -233↓37.9% | -169↓13.7% | -149 | |
| EBIT | -440↓38.6% | -317↓34.5% | -236↓38.0% | -171↓14.0% | -150 | |
| Interest & Other Income | ||||||
| Net Interest Income | 24↓12.1% | 27↑252.3% | 8 | 0.00↓100.0% | 0.74 | |
| Interest Income | 30↑10.9% | 27↑252.3% | 8↑161.9% | 3↑293.1% | 0.74 | |
| Interest Expense | 6 | 0.00 | 0.00↓100.0% | 3 | 0.00 | |
| Non-Operating Income | -28↓6.4% | -26↓325.2% | -6 | 0.00 | 0.00 | |
| Other Income / Expenses | 22↓17.0% | 26↑325.2% | 6↑117.4% | 3↑290.1% | 0.73 | |
| Income Before Tax | -446↓40.6% | -317↓34.5% | -236↓40.4% | -168↓12.6% | -149 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -446↓40.6% | -317↓34.5% | -236↓40.4% | -168↓12.6% | -149 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -446↓40.6% | -317↓34.5% | -236↓40.4% | -168↓12.6% | -149 | |
| Bottom-Line Net Income | -446↓40.6% | -317↓34.5% | -236↓40.4% | -168↓12.6% | -149 | |
| EPS (Basic) | -3.47↓3.0% | -3.37↑14.7% | -3.95↓22.3% | -3.23↓10.2% | -2.93 | |
| EPS (Diluted) | -3.47↓3.0% | -3.37↑14.7% | -3.95↓22.3% | -3.23↓10.2% | -2.93 | |
| Weighted Average Shares | 128↑36.4% | 94↑57.7% | 60↑14.8% | 52↑2.1% | 51 | |
| Weighted Average Diluted Shares | 128↑36.4% | 94↑57.7% | 60↑14.8% | 52↑2.1% | 51 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.